April 8, 2020 -- Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic collaboration partners for therapy development.
Since January, the company has designated over 100 expert research and development scientists to contribute to projects for potential treatment solutions for COVID-19. The company has established additional collaborations with academia, biotech, and other pharmaceutical companies.
- Boehringer Ingelheim is committing over 11,000 hours in R&D to the Innovative Medicines Initiative.
- The company has also joined forces with the Bill & Melinda Gates Foundation COVID-19 Therapeutics Acceleration.
- Six of the company's antiviral compounds and 43 pharmacological tool compounds have been shared on the open innovation portal opnMe.com.
Additionally, Boehringer Ingelheim has made available $6.4 million in donations for emergency aid. The company is also offering paid leave to join external organizations to bring COVID-19 relief.
Committed to further contributions as needed, the company is working in broad strokes to tackle the virus, according to Cyrille Kuhn, PhD, executive director of research at Boehringer Ingelheim.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
